Prime Medicine, Inc.
Prime Medicine, Inc.（PRME）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
prme · 股价预测 · 9 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 9 位华尔街分析师
Buy
9 位分析师
共识
评级分布
12 个月目标价
High
$23.00
Consensus
$17.25
+472.1% upside
Low
$12.00
Median: $17 · Last Close: $3.02
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$17.25
472.1% upside
High Target
$23
662.9%
Low Target
$12
298.0%
Current Price
$3.02
as of today
Based on analyst price targets, the PRME stock price prediction for the next 12 months ranges from $12 to $23. The consensus PRME price forecast of $17.25 implies 472.1% upside from the current price of $3.02.
短期股价预测
Bear算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.05 | ↑ 1.22% |
1-day model range: $3.02–$3.09. Peak: $3.09 (+1.22%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -50.0% |
| 2028 | $1 | -63.7% |
| 2029 | $1 | -69.2% |
| 2030 | $1 | -71.8% |
| 2031 | — | -73.1% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PRME · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-11 | Citigroup | Maintains | Neutral→Neutral |
| 2025-11-10 | Chardan Capital | Maintains | Buy→Buy |
| 2025-08-12 | Citigroup | Maintains | Neutral→Neutral |
| 2025-08-08 | Chardan Capital | Maintains | Buy→Buy |
| 2025-05-27 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2025-05-20 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2025-05-20 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2025-05-20 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-05-19 | Chardan Capital | Maintains | Buy→Buy |
| 2025-03-20 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Prime Medicine, Inc. (PRME) stock. Of the recent 25 rating actions, 1 were upgrades and 3 were downgrades. 9 analysts currently cover PRME.
分析师推荐趋势
PRME analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$13M
↓ 58.7% YoY
Revenue Next Year
$23M
↑ 74.1% YoY
EPS This Year
$-1.00
EPS Next Year
$-0.91
↓ 8.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast PRME EPS of $-1.00 for the current fiscal year, based on estimates from 9 analysts. The PRME revenue forecast is $13M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
PRME 股价预测由两类独立数据源支撑：来自 9 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。PRME 的共识目标价为 $17.25（+472.1% 上行空间），分析师共识为 Buy。
PRME 的短期预测（明日）为 $3.05（+1.22%）。 PRME 对 2027 年的股价预测均值为 $2。 PRME 对 2030 年的预测区间为 $1–$1。
Prime Medicine, Inc. 在 NASDAQ 上市，代码 PRME。PRME 在 2027 年的整体展望偏积极，在覆盖分析师中约 56% 对应 Buy 共识。
常见问题
PRME 预测 · 8 个问题根据 9 位华尔街分析师，PRME 的 12 个月平均目标价为 $17.25，最高 $23.00、最低 $12.00。若有图表，中位目标价可在上方查看。相对当前价 $3.02，隐含约 +472.1% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.